Azopharma Product Development Group, Inc. and Accu-Break Pharmaceuticals, Inc. (ABP) have signed a strategic alliance agreement in which Azopharma will develop products based on ABP’s Accu-Break tablet technologies. The agreement spans five years and Azopharma Product Development Group will also provide sales and marketing support.     Dr. Allan Kaplan, chief executive officer of ABP stated, “ABP’s patented Accu-Break technologies create an inactive break layer in tablets, allowing them...